Head-to-head evidence
10-1074 vs Lotivibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
10-1074
Developed by Gilead Sciences and partners
NCT03707977 · Phase 1/2 · completed
This was a small, nonrandomized, open-label study without a comparator arm, enrolling 30 children overall and evaluating viral-load and safety outcomes descriptively. The primary viral outcomes were reported as 11 of 25 below 400 copies/mL and 10 of 25 below 40 copies/mL at Week 24, but there was no controlled comparison or formal significance test.
Next expected readout: September 2029 · NCT07820813 (registry estimate)
Lotivibart
Developed by ViiV Healthcare
NCT04871113 · Phase 2 · completed
Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.
Next expected readout: January 2027 · NCT07053384 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 10-1074's landscape · Lotivibart's landscape